Skip to main content

Rhophylac ZLB Bioplasma AG, Switzerland - Treatment for Prevention of Rho(D) Sensitization

Rhophylac is a highly purified, plasma-derived product comprised of Rho(D) Immune Globulin (Human) for IV or IM administration. Rhophylac is primarily indicated for the prevention of hemolytic disease of the fetus and newborn (HDN), and also indicated to prevent Rho(D) sensitization after transfusion of Rh-positive blood type to Rh-negative patient.

Related articles

Rhophylac (Rh0(D) immune globulin intravenous (human)) FDA Approval History

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.